Immix Biopharma, Inc.
IMMX
$2.12
$0.020.95%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 12.02M | 11.75M | 11.38M | 10.04M | 9.51M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 23.78M | 21.77M | 22.67M | 23.06M | 20.19M |
Operating Income | -23.78M | -21.77M | -22.67M | -23.06M | -20.19M |
Income Before Tax | -23.09M | -20.87M | -21.66M | -22.00M | -19.20M |
Income Tax Expenses | 40.60K | 42.00K | 41.00K | 38.30K | 34.00K |
Earnings from Continuing Operations | -23.13 | -20.91 | -21.70 | -22.04 | -19.24 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | 0.00 | 12.90K | 85.00K | 150.90K | 214.10K |
Net Income | -23.13M | -20.90M | -21.61M | -21.89M | -19.02M |
EBIT | -23.78M | -21.77M | -22.67M | -23.06M | -20.19M |
EBITDA | -23.66M | -21.70M | -22.64M | -23.05M | -20.18M |
EPS Basic | -0.78 | -0.71 | -0.78 | -0.85 | -0.84 |
Normalized Basic EPS | -0.49 | -0.44 | -0.49 | -0.53 | -0.52 |
EPS Diluted | -0.78 | -0.71 | -0.78 | -0.85 | -0.84 |
Normalized Diluted EPS | -0.49 | -0.44 | -0.49 | -0.53 | -0.52 |
Average Basic Shares Outstanding | 118.67M | 117.47M | 111.21M | 103.43M | 92.58M |
Average Diluted Shares Outstanding | 118.67M | 117.47M | 111.21M | 103.43M | 92.58M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |